VSIR and neoplasm: After the initiation of ICBs, responders experienced genomic contraction, loss of the tumor cells expressing specific neoantigens, expansion of specific T cells targeting the corresponding neoantigens, and upregulation of other checkpoints (such as TIGIT, TIM-3, and VISTA), with the left cancer clones more resistant to the activated immunity (41).